Stabilization and quantitative measurement of nicotinamide adenine dinucleotide in human whole blood using dried blood spot sampling
Analytical and Bioanalytical Chemistry · 2023-02 · 415 (5) · 775-785
DOI: 10.1007/s00216-022-04469-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Analytical and Bioanalytical Chemistry, online erschienen am 11.12.2022. Verfasst von Ryo Matsuyama und 5 weiteren Autor:innen. Beteiligte Einrichtung: Nutraceutical Group, Healthcare New Business Division, Teijin Limited, Hino, Tokyo, Japan. r.matsuyama@teijin.co.jp. Hauptthemen laut MEDLINE: NAD, Aging. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Nicotinamide adenine dinucleotide (NAD + ) is a coenzyme essential for energy production. Recently, associations between NAD + and aging-related diseases have been reported, and NAD + precursors that increase NAD + concentration in the body have been acknowledged as anti-aging supplements. However, there have been only a few studies on the link between aging or aging-related diseases and human blood NAD + concentration because NAD + and its precursors are unstable in blood and difficult to measure. Therefore, we aimed to construct a quantitative NAD + measurement method that is simpler than the existing methods. The calibration standards of NAD + showed good linearity (0.9936 to 0.9990) in the range of 0.25 to 200 μM, and the lower limit of quantification was 0.5 to 2 μM. We found that QIAcard FTA DMPK-B maintained NAD + stability of 85% or more for at least 2 weeks at 4 °C and 1 week at room temperature using the dried blood spot method. Additionally, NAD + stability in the blood extraction solution was more than 90% for 2 months. To our knowledge, there has been no report on a quantitative NAD + measurement method in human whole blood that can be performed with as little as 5 μL of blood and can be easily implemented at both medical clinics and private homes. Our simple and convenient method has the potential to become the gold standard for NAD + measurement in blood. It is expected to contribute to the acceleration of research on the correlation between aging or aging-related diseases and NAD + concentration in human blood.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nutraceutical Group, Healthcare New Business Division, Teijin Limited, Hino, Tokyo, Japan. r.matsuyama@teijin.co.jp.
- Discovery DMPK Research Group, Toxicology & DMPK Research Department, Teijin Institute for Bio-Medical Research, Teijin Pharma Limited, Hino, Tokyo, Japan. r.matsuyama@teijin.co.jp.
- Discovery DMPK Research Group, Toxicology & DMPK Research Department, Teijin Institute for Bio-Medical Research, Teijin Pharma Limited, Hino, Tokyo, Japan.
- Nutraceutical Group, Healthcare New Business Division, Teijin Limited, Hino, Tokyo, Japan.
- NOMON Co. Ltd., Kasumigaseki, Chiyoda-Ku, Tokyo, Japan.
Zitieren
APA
Matsuyama, R., Omata, T., Kageyama, M., Nakajima, R., Kanou, M., & Yamana, K. (2023). Stabilization and quantitative measurement of nicotinamide adenine dinucleotide in human whole blood using dried blood spot sampling. Analytical and Bioanalytical Chemistry, 415(5), 775-785. https://doi.org/10.1007/s00216-022-04469-7
Vancouver
Matsuyama R, Omata T, Kageyama M, Nakajima R, Kanou M, Yamana K. Stabilization and quantitative measurement of nicotinamide adenine dinucleotide in human whole blood using dried blood spot sampling. Analytical and Bioanalytical Chemistry. 2023;415(5):775-785. doi:10.1007/s00216-022-04469-7
BibTeX
@article{Matsuyama2023,
author = {Matsuyama, Ryo and Omata, Tomoyo and Kageyama, Michiharu and Nakajima, Ryota and Kanou, Masanobu and Yamana, Kei},
title = {Stabilization and quantitative measurement of nicotinamide adenine dinucleotide in human whole blood using dried blood spot sampling},
journal = {Analytical and Bioanalytical Chemistry},
year = {2023},
volume = {415},
number = {5},
pages = {775--785},
doi = {10.1007/s00216-022-04469-7}
}
EUVIMED